Business Wire

MA-CARE-ACCESS

18.3.2024 08:06:32 CET | Business Wire | Press release

Share
Care Access Opens New Clinical Research Site in Warsaw, Poland

Care Access, a global clinical research site company helping to accelerate the future of medicine, has opened its newest research site in Warsaw, Poland. The company’s expansion in Poland reinforces its commitment to improving access to clinical research globally through its innovative model of bringing clinical trials wherever they are needed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318427054/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Care Access - Warsaw research site is now open. (Photo: Business Wire)

In recent years, Care Access has been active in clinical research across Europe, and now, by establishing a new facility in Warsaw, Care Access is further expanding its European services aimed to implement its industry-leading research capabilities, such as its Community Screening Program, Sites On Demand, and Mobile Research Site Infrastructure. These capabilities have shown to accelerate research study enrollment by adapting to the unique makeup of each community and providing more convenient ways to participate in clinical trials.

“Poland plays an important role in bringing the future of medicine to reality,” said Rupi Bancil, Senior Vice President of Global Study Operations & Expansion for Care Access. “The Warsaw site will improve access to advanced health screenings and research opportunities to communities throughout Poland.”

Collaboration with local physicians is a key approach to how Care Access improves access to clinical research in more communities. With a centralized staff of research professionals and state-of-the-art equipment, infrastructure, and processes, Care Access takes on a great deal of the administrative and logistical burden so partnering physicians can spend more time focusing on their patients.

Care Access has previously expanded its global network of research sites through the acquisition of IBPClin in Brazil in 2022 and the establishment of its first Canadian research site in Cape Breton in 2023. The addition of the Warsaw location strengthens Care Access' global research site network, enabling the company to conduct trials across multiple therapeutic areas and respond to emerging global health needs.

About Care Access

Care Access is a global clinical research site company helping to accelerate the future of medicine. With a global network of over 200 research sites, Care Access supports research studies conducted by hundreds of top biopharmaceutical companies. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation.

For research sponsors, Care Access offers three core services: (1) global network of research sites, (2) community screenings to expand a study’s reach, and (3) on-demand staffing, space expansion, and training services to support all research sites on a study.

To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240318427054/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gustave Roussy and One Biosciences Partner to Bring Single Cell to Clinical Practice for Precision Oncology19.5.2026 13:02:00 CEST | Press release

Gustave Roussy partners with One Biosciences, a techbio company that harnesses single cell technology and AI to develop advanced precision diagnostics. The collaboration aims to further demonstrate the feasibility and impact of integrating single nuclei transcriptomic analysis into the patient care pathway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519540709/en/ Gustave Roussy, Europe’s leading cancer center, is teaming up with One Biosciences to harness the cutting-edge potential of OneMapTM, the single-cell and AI-powered solution helping to enhance precision oncology solutions. By analyzing anonymized frozen samples across four cancer indications, One Biosciences will deploy OneMapTM to generate ultra-high-resolution single-cell data, unlocking the hidden functional diversity of each tumor with unparalleled precision. Prof. Sophie Postel-Vinay, oncologist at Gustave Roussy, team leader in Inserm unit U981 at Gusta

InterSystems IntelliCare Becomes the First AI-Native EHR to Achieve EU Medical Device Regulation Certification19.5.2026 13:00:00 CEST | Press release

Regulatory milestone reaffirms InterSystems as a leading provider of enterprise-grade AI applications InterSystems, a creative data technology provider powering more than one billion health records globally, today announced that its electronic health record (EHR) solutions have been certified as Class IIa Medical Devices under Regulation (MDR) certification under Regulation (EU) 2017/745. This approval marks the first fully unified AI-native EHR to achieve MDR Class IIa certification in the European Union. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519124986/en/ This certification demonstrates that InterSystems AI-native EHR meets stringent EU safety and quality standards. This key milestone has significant implications for how healthcare organizations can responsibly scale AI while building confidence among healthcare providers and regulators. InterSystems has secured MDR certification for InterSystems IntelliCare™,

Venionaire Capital Mandated to Structure KISAB’s Next Growth Round19.5.2026 12:41:00 CEST | Press release

Growth round to target growth private equity and strategic investors as KISAB advances its 8-inch BPD-free SiC wafer platform Venionaire Capital has been mandated by Kiselkarbid i Stockholm AB (“KISAB”) to structure and support the company’s next growth round. The mandate includes investor relations, investor communications and strategic financing preparation, targeting growth private equity and strategic investors. KISAB is a Sweden-based silicon carbide semiconductor materials company focused on advanced SiC substrates for power electronics. The company publicly highlights its 8-inch BPD-free n-type silicon carbide wafers, with the 8-inch platform representing an important technological step for next-generation high-performance power electronics. KISAB has previously attracted approximately EUR 24 million across several financing rounds. Publicly named investors include Fairpoint Capital, Industrifonden and Ingka GreenTech. Venionaire Capital will now support the company in sharpenin

motif Launches Clarity, a First-of-Its-Kind AI Financial Intelligence System19.5.2026 12:39:00 CEST | Press release

Clarity applies contextual understanding to market intelligence, enabling auditable, high-quality AI wealth advisory for financial institutions motif, the AI wealth advisory company backed by Liminal (a venture creation group founded by Temasek), today launched Clarity, an AI financial intelligence system that tracks how markets, assets and financial relationships connect, and how and why they change over time, building enriched connections that deliver the kind of structured, sourced insight that financial institutions have never had, even with dedicated analyst teams. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511241653/en/ motif Launches Clarity, a First-of-Its-Kind AI Financial Intelligence System Financial institutions integrate Clarity into their products so customers can make better-informed investment decisions, while analysts and product teams use it to track market shifts and plan accordingly. Informed inves

Axelspace Announces Launch of Seven GRUS-3 Earth Observation Microsatellites, No Earlier Than July 202619.5.2026 10:30:00 CEST | Press release

Enabling Wide-Area, High-Frequency Observation to Expand the Applications of Satellite Data Axelspace Corporation, a leading developer and operator of microsatellites dedicated to realizing its vision of “Space within Your Reach,” announced today that GRUS-3, a set of seven next-generation Earth observation microsatellites, is scheduled to be launched no earlier than July 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519449959/en/ Seven flight model of GRUS-3 next-generation Earth observation microsatellites ©Axelspace The seven GRUS-3 microsatellites will launch aboard the Transporter-17 rideshare mission via Exolaunch, a global leader in launch mission management, satellite integration, and deployment services, from Vandenberg Space Force Base in California, USA. We currently operate five optical Earth observation microsatellites, GRUS-1, under our Earth observation data service, AxelGlobe. With the launch of its

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye